Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.

Recommended AI News: WiMi Developed RPSSC Technology With Multiple Advantages in Hyperspectral Image Processing

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum”

Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade. By leveraging its unique Foundation Model, Paige has surpassed these limitations. With data derived from over 4 million digitized slides, Paige’s innovative approach removes the constraints of developing single tissue products, making it possible to efficiently create cancer detection AI applications across a multitude of tumor types, a first in AI-based cancer diagnosis.

“The early success of our Foundation Model has been possible due to the size, quality, and diversity of the datasets we used to build it,” said Siqi Liu, PhD, director of AI Science at Paige. “Paige has access to one of the largest and most highly regarded pathology datasets globally, which allows us to leverage cutting-edge deep-learning approaches to train systems to detect common, complex, and even very rare cancer entities. Paige’s development provides the pathology community with the most powerful tools for diagnosis, prognosis, biomarker development, and targeted selection of patients for precision therapy,” he continued.

The exceptional performance of Paige’s multi-cancer application across various tissue types is considered state-of-the art in cancer pathology AI. Paige is committed to ensuring its AI applications are clinical grade and will therefore continue to seek FDA regulatory oversight for products based on the Foundation Model technology.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

“We see FDA clearance as being critical to ensure that regulatory and safety standards are being upheld in the application of AI in cancer diagnostics across tumor types,” said Andy Moye, CEO of Paige. “Paige remains at the forefront of innovation and regulatory milestones, and we expect this multi-tissue detection model to benefit patients, pathologists, and the broader medical community. Our commitment to excellence is exemplified by this groundbreaking achievement, marking a significant leap forward in cancer diagnostics.”

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum,” said Razik Yousfi, Senior Vice President of Technology at Paige. “By combining the outputs of the Foundation Model with data types from other modalities, including genomics, radiology, and other health data, one can derive exponentially greater insights about the nature of cancer, its behavior, and response to specific treatments.”

Recommended AI News: OPENLANE Launches Visual Boost AI to Pinpoint Vehicle Damage

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types appeared first on AiThority.

Company extends preclinical and clinical histopathology/molecular pathology solutions to researchers on both sides of the Atlantic

StageBio, a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research, announced its acquisition of TPL Path Labs of Freiburg, Germany. The combined organization offers an expanded array of histopathology, molecular pathology, toxicology, digital image analysis and related solutions to biopharma, medical device and academic researchers across the U.S., Europe and beyond. StageBio is a portfolio company of Ampersand Capital Partners.

The acquisition expands StageBio’s preclinical and clinical laboratory resources, adding a GLP/GCLP-compliant lab facility and staff in Germany to the company’s existing six GLP-compliant lab facilities and two GLP specimen archive sites in the U.S. This strengthens StageBio’s ability to deliver services internationally, reducing the need to ship study materials overseas. Uniform technology platforms and protocols across the U.S. and European operations ensure consistent quality, accuracy and efficiency.

Recommended AI News: Vyopta And Barco Overture Offer Integrated Room And Video Collaboration Monitoring Solution

With more than 175 professionals, including 30 experienced pathologists, the combined organization has the scale to serve the largest multinational customers, while retaining the highly responsive and personalized service for which StageBio is known.

Together, StageBio and TPL Path Labs offer an exceptionally broad array of solutions across the preclinical, translational and clinical continuum—from study protocol development through necropsy, histology, pathology, imaging and analysis. In particular, the acquisition enhances StageBio’s ability to support clinical investigators in the areas of biomarker development, tissue cross-reactivity (TCR) and immunohistochemistry.

Recommended AI News: Ivacy VPN & Startpage Collaborate To Strengthen Internet Users’ End-To-End Online Privacy Experience

“The addition of TPL Path Labs to StageBio represents a significant step in our global strategy to support researchers with the broadest range of quality solutions at every stage of discovery through clinical development,” said Tom Galati, StageBio CEO. “The expertise and sophisticated capabilities of the TPL team integrate perfectly with StageBio’s, enabling us to deliver solutions with a combination of depth, breadth and quality that is unmatched in the markets we serve.”

“Becoming part of StageBio is great news for TPL Path Labs’ customers across Europe, Australia and Asia,” said Ayse Bal, TPL Path Labs General Manager. “By expanding our capabilities, scale and geographic reach, the combined organization enables us to respond even more rapidly and effectively to our customers’ needs. StageBio shares our commitment to customer success and responsive service, making this an ideal match.”

Recommended AI News: ThinkIQ Digital Manufacturing Pioneer Raises $11.6 Million

The post StageBio Expands Its Global Presence With Acquisition of TPL Path Labs appeared first on AiThority.